K36’s lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation. We are developing KTX-1001 to provide a targeted therapy that specifically addresses the underlying cause of cancer for these multiple myeloma patients. KTX-1001 will be the first therapeutic agent to enter the clinic that directly targets overexpression of MMSET.

Innovo Therapeutics is committed to discovering and developing the next generation of protein degraders in areas of high unmet medical need. Our extensive experience in drug discovery, combined with our unique expertise in targeted protein degradation, allows us to quickly develop an extensive compound library of novel and drug-like structures which generates high-quality leads. We have a powerful targeted protein degradation platform called TriNovo. Coupled with a proprietary phenotypic screening platform, our scientists build and rapidly expand a high-quality, differentiated pipeline. Our competitive advantage is a differentiated drug discovery approach, allowing us to advance our pipeline quickly. We continue to drive value through highly validated biology and our differentiated, high-throughput chemistry platform. We focus on execution, rapidly growing our pipeline through corporate and academic alliances. We have worldwide exclusive rights to Rosmantuzumab, anti-RSPO2 mAB, which is a Phase 2 clinical program. We are actively engaged in further pharma partnerships discussion to advance our pipeline programs. We are maximizing Innovo’s expertise, productivity, and efficiency with the Innovo US team’s proven drug discovery experience, leveraging our expertise, and optimizing China’s rich pre-clinical resources and infrastructure to build a world-class, global biopharma company.

I serve as the biotech industry board representative for MedStar Health Research Institute, which provides support for research programs throughout MedStar Health. MedStar Health is a not-for-profit, regional healthcare system with nine hospitals and more than 20 other health-related services in greater Washington DC metro area and academically affiliated with Georgetown University. Governance Committee Chair 2022.

N-Power Medicine, we are a venture-backed startup that aims to establish a new paradigm for speed and certainty in oncology drug development by transforming routine patient care data to clinical trial grade data to accelerate more inclusive industry-sponsored clinical trials.

Biotech/Pharma, Digital Health, Academic/Health Systems Management Consultant specializing in strategy, business development, operations and integration in areas of clinical research, manufacturing, clinical operations and BD/AM. Strategic advisor for C-suite executives for partnering and lead business development and fundraising activities. Lead executive-level discussions, including target partner outreach, pitch preparation and management presentations and due diligence process. Specializes in international and partnering relationships.

Lead the largest biopharma $74 billion integration, planning & operations, board, and leadership communication. Accountable for cross functional integration management teams (IMT) programs, across international markets, enabling functions (HR, IT, Finance) and BUs. Lead global enterprise change champions network, drive complex interdependencies, decision-making and accountability across IMTs.

As Head of Business, Strategy & Integration (BSI) and Product Leadership, I lead and owned the Global Pharmaceutical Development, Operations and Manufacturing Strategic planning process, Project Management Office, Operational Excellence, and Technical Commercial Product leadership functions. My functionally diverse team worked to align the overall strategy, project portfolio and governance with Celgene’s commercial, clinical and manufacturing development strategy, product portfolio and program governance. Through optimization of commercialization strategies and alignment of internal/external stakeholders, BSI supports value creation through collaborative innovation, decision making and planning. Organized and operationalized three new Product Launch readiness teams and management of information to organization. Led late stage oncology asset CMC transition-INREBIC® (Fedratinib); Transition Leader for late stage asset cross functional team (marizomib). Identified life cycle management opportunities, including facilitating decisions for Acceleron developing (sotatercept) for PAH and structure for partnership & transition.

Senior Director 2013-September 2016Successfully launched and managed over $1B of Celgene's strategic collaboration investments. Led alliances through its life cycle process from diligence, launch, amendments, and termination; a variety of deal structures; option to acquire, asset purchase, collaboration and across oncology, immunology & inflammation franchises, early R&D through medical affairs. Implemented alliance governance, contract management and ensure milestones deliverables. I led late-stage oncology asset acquisition (marizomib - brain penetrant irreversible proteasome inhibitor) and was the transitional Leader for asset (INREBIC) integration team. I am proud to be part of the BD & Global Alliances team that earned Celgene’s reputation as the Partner of Choice in BCG Survey for two consecutive award cycles.

I led a talented global team and provided the strategic vision for all clinical contract activities, including investigator grants, oversee and managed clinical trial site contracts for Celgene sponsored agreements. Collaborated with legal and finance organization to improve processes and tools. Worked with regional and therapeutic heads to optimize site contracting process to meet the corporate MIP targets, and develop new operating model paradigms for partnerships with sites, and CROs. Responsible for ensuring investigator grants fair market value and improved performance metrics and targets for study start-up activities, including implementation of central IRB model.

Contracts and Outsourcing: Investigator agreements, negotiation and modification of Phase II-IV clinical trials agreements and budgets with research sites. Responsible for insuring execution and monitoring of quality of agreements for Medical Affairs (Investigator-initiated research and Publications), Outcomes Research across all Pfizer's business units and Functional Service Providers for Development Operations. Managed and supervised 10 FTEs and 2 contractors. Collaborated and monitored strategic partnership CROs/FSP to ensure timely study start-up activities. Lead global investigator grant cost savings and benchmarking initiatives.Created “Face of Pfizer” with Institutions’ Grants and Contract offices through relationship management initiative to improve site study start up processes. Lead continuous improvement activities by improving Study Start-Up through process reviews and evaluation and alignment with internal and external resources. Lead Lean Six Sigma Green Belt project in improving US academic medical centers contract cycle time and achieved 55% improvement.

Lead instructor for core graduate course in Human Trials II, Drug and Biologic Development and Clinical Research Finance course includes NIH funding, federal cost principles, and industry business practices of clinical research financial management and venture capital financing. Course involves pharmaceutical and project management, clinical development as a product/biologic proceeds from an IND to NDA.• Alpha Eta Honor Society – Outstanding Faculty Honor Award, The George Washington University May 2004

Created a new central office for Clinical and Health Service Research for 11 acute care public hospitals, clinics and long-term care facilities of New York City. Primary responsibilities included establishing policies and providing oversight for all clinical and health service research throughout the Corporation. Lead the Research Oversight Committee. Reviewed and authorized all medical research that is conducted at Corporation facilities to assure compliance with corporate policies including the HHC Clinical Investigation and Research Policy and Guidelines, and federal and state regulations. Served as the Corporation’s liaison to governmental and professional agencies on research matters, and was responsible for seeking additional clinical and health services research grants.

Led the Clinical Trials Network to ensure its strategic direction, operational and financial success. Managed clinical and regulatory staff to ensure timely, effective and ethical conduct of clinical trials across multiple therapeutic areas. Implement the review and revision of SOPs. Successfully tripled number of studies, increased subject enrollment and doubled monthly study revenue in the first six months of leadership. Develop new business contacts with pharmaceutical sponsors for new trial opportunities. Designed and implemented specific subject recruitment strategies to deliver enrollment targets. Led business development activities such as cultivating relationships with private practice physicians, industry sponsors, submitting RFP’s and public relations campaign across local communities. Developed new investigator-initiated protocols, ensure appropriate regulatory approvals with IRB and FDA PI-sponsored INDs and ensure funding from federal, foundation and industry grant process. Developed process for hospital research registration/payment to ensure compliant hospital billing process for clinical trials patients to industry sponsored grants. Presented status of research mission to the Board of Directors and facilitate the development of research strategic plan with Education and Research subcommittee of the Board.

Responsibilities included developing strategies of a centralized clinical trial office; implementing policies for the conduct of clinical trials, providing legal, administrative, regulatory and fiscal management across all therapeutic research programs. Provided diverse business services, e.g., negotiating contracts and budgets; providing fiscal management; writing protocols, study conduct, marketing and business development. Designed and implemented a strategic plan to achieve streamlined and quality services and to foster the growth of clinical research at the NYU Medical Center. Executed business development strategies to strengthen with key and industry contacts.

Provided recommendations and solutions to complex organizational, fiscal and operational problems in clinical research settings, including academic medical centers, teaching hospitals, integrated health systems, and pharmaceutical fortune 500 companies. Evaluated compliance and regulatory issues in research administration and clinical trials management in various healthcare settings.

Worked with the Chief Operating Officer on integration projects to improve operations, financial performance, and administrative functions for three hospitals, home health, and other entities of the health system.

Cardiovascular Research Institute - Managed federal and industry grants, clinical trials, and responsible for financial management of the Institute.

Worked with the Financial Planning, Analysis & Reporting team under the Chief Financial Officer

Department of Pharmacy Services - Responsible for working with Director, Clinical Pharmacists, Pharmacy Technicians, and Investigational Pharmacists. Coordinated the Pharmacy & Therapeutics Committee and organized Hospital Drug Fair with pharmaceutical companies.